Skip to main content

Advertisement

Table 2 Estimated median time to relapse

From: Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Canakinumab Dose regimen No. of subjects No. of periods Median time to relapse (days) 95% confidence interval
2 mg/kg s.c. 4 22 48.6 29.3 to 67.9
2 mg/kg s.c. + rescue i.v. 2** 11 51.7 27.0 to 76.5
  1. ** Two subjects received rescue medication for some periods. In one out of these two pediatric patients, data of periods in which rescue medication was not given were analyzed with the 2 mg/kg s.c. group, while data of periods in which rescue medication was given were analyzed separately with the 2 mg/kg s.c. + rescue i.v. group.